Free Trial

Scilex (SCLX) Competitors

Scilex logo
$11.96 +1.24 (+11.57%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$11.92 -0.04 (-0.34%)
As of 07/25/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCLX vs. IMAB, TLSA, DERM, CYBN, DMAC, NVCT, PBYI, ACRS, ENGN, and CCCC

Should you be buying Scilex stock or one of its competitors? The main competitors of Scilex include I-Mab (IMAB), Tiziana Life Sciences (TLSA), Journey Medical (DERM), Cybin (CYBN), DiaMedica Therapeutics (DMAC), Nuvectis Pharma (NVCT), Puma Biotechnology (PBYI), Aclaris Therapeutics (ACRS), enGene (ENGN), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry.

Scilex vs. Its Competitors

Scilex (NASDAQ:SCLX) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

I-Mab has a net margin of 0.00% compared to Scilex's net margin of -146.93%. Scilex's return on equity of 0.00% beat I-Mab's return on equity.

Company Net Margins Return on Equity Return on Assets
Scilex-146.93% N/A -82.65%
I-Mab N/A -19.81%-18.63%

69.7% of Scilex shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 7.9% of Scilex shares are held by insiders. Comparatively, 22.1% of I-Mab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Scilex presently has a consensus price target of $455.00, suggesting a potential upside of 3,704.35%. I-Mab has a consensus price target of $6.00, suggesting a potential upside of 184.36%. Given Scilex's higher probable upside, research analysts plainly believe Scilex is more favorable than I-Mab.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scilex
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
I-Mab
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

In the previous week, I-Mab had 1 more articles in the media than Scilex. MarketBeat recorded 3 mentions for I-Mab and 2 mentions for Scilex. Scilex's average media sentiment score of 0.93 beat I-Mab's score of 0.46 indicating that Scilex is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scilex
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
I-Mab
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

I-Mab has lower revenue, but higher earnings than Scilex.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scilex$56.59M1.47-$72.81M-$29.02-0.41
I-MabN/AN/A-$22.23MN/AN/A

Scilex has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Summary

I-Mab beats Scilex on 8 of the 13 factors compared between the two stocks.

Get Scilex News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCLX vs. The Competition

MetricScilexMED IndustryMedical SectorNASDAQ Exchange
Market Cap$74.52M$3.06B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E Ratio-0.4121.1828.1020.05
Price / Sales1.47288.50432.4490.07
Price / CashN/A42.7636.2258.56
Price / Book-0.438.378.665.87
Net Income-$72.81M-$55.19M$3.25B$258.55M
7 Day Performance34.99%5.88%4.23%3.74%
1 Month Performance125.66%17.33%10.52%11.75%
1 Year Performance-79.66%4.42%34.41%18.03%

Scilex Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCLX
Scilex
2.3844 of 5 stars
$11.96
+11.6%
$455.00
+3,704.3%
-79.9%$74.52M$56.59M-0.4180News Coverage
IMAB
I-Mab
2.8566 of 5 stars
$2.14
+0.5%
$6.00
+180.4%
+51.8%$174.75M$3.89M0.00380Gap Down
TLSA
Tiziana Life Sciences
1.2071 of 5 stars
$1.48
flat
N/A+93.1%$172.94MN/A0.008
DERM
Journey Medical
2.334 of 5 stars
$7.41
+3.6%
$9.50
+28.2%
+42.4%$172.65M$56.13M-19.0090High Trading Volume
CYBN
Cybin
2.7149 of 5 stars
$7.47
-2.2%
$85.00
+1,037.9%
N/A$171.99MN/A-1.7150
DMAC
DiaMedica Therapeutics
1.5004 of 5 stars
$4.01
+10.5%
$8.00
+99.5%
+36.9%$171.95MN/A-6.2720News Coverage
Insider Trade
High Trading Volume
NVCT
Nuvectis Pharma
2.8678 of 5 stars
$8.22
+4.3%
$17.00
+106.8%
+17.5%$171.75MN/A-7.278Positive News
PBYI
Puma Biotechnology
4.2383 of 5 stars
$3.45
+1.8%
$7.00
+102.9%
-16.8%$171.22M$230.50M4.48200Upcoming Earnings
ACRS
Aclaris Therapeutics
2.3809 of 5 stars
$1.58
+0.6%
$8.71
+451.5%
+25.9%$171.08M$18.72M-1.14100
ENGN
enGene
2.8343 of 5 stars
$3.34
+0.9%
$23.29
+597.2%
-58.9%$170.67MN/A-2.0231
CCCC
C4 Therapeutics
3.1629 of 5 stars
$2.38
+6.7%
$12.00
+404.2%
-64.9%$169.00M$35.58M-1.62150Positive News
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:SCLX) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners